Provirex

Executive Summary

Provirex is a German biotechnology company developing genome editing therapies to achieve a functional cure for HIV. Its proprietary technology utilizes highly specific designer recombinases, such as Brec1, to precisely excise integrated HIV DNA from infected host cells, offering a potential one-time curative treatment. The company operates a specialized ATMP manufacturing facility in Hamburg, positioning itself for personalized cell therapy production. Founded in 2018, Provirex is a private company with no disclosed funding or valuation, but its innovative approach addresses a significant unmet need in infectious disease.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase I clinical trial for Brec1-based HIV therapy60% success
• Q2 2026Publication of preclinical proof-of-concept data in peer-reviewed journal80% success
• H1 2027Strategic partnership with a larger biopharma for co-development50% success